Anavex Life Sciences (AVXL) announced positive topline results from its placebo-controlled Phase 2 clinical study evaluating ANAVEX3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication. The study achieved its primary endpoint demonstrating that ANAVEX3-71 was safe and well-tolerated. The safety profile was consistent with previous studies of ANAVEX3-71 in healthy volunteers.
The company noted that, in addition to meeting the primary safety endpoint, secondary and exploratory analyses revealed encouraging trends in several outcome measures. The study showed positive trends in objective electroencephalography and event-related potential biomarkers of schizophrenia.
Shares of Anavex are up 7% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.